Skip to main content

Pre-Treatment with BET Inhibitors Increases the Sensitivity of Cancer Cell Lines to Cisplatin and Oxaliplatin

Wicks, Andrew (2017) Pre-Treatment with BET Inhibitors Increases the Sensitivity of Cancer Cell Lines to Cisplatin and Oxaliplatin. Master of Science by Research (MScRes) thesis, University of Kent,. (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided)

PDF
Restricted to Repository staff only until July 2020.
Contact us about this Publication Download (1MB)
[img]

Abstract

Platinum compounds, such as cisplatin, carboplatin and oxaliplatin are utilised widely in therapeutic strategies against a range of malignancies, for instance Neuroblastoma and Ovarian cancer. These compounds elicit anticancer effects by damaging DNA via the formation of crosslinks with nitrogenous bases, leading to DNA damage responses and the induction of apoptotic signalling. Although these compounds may produce promising initial responses, the emergence and establishment of chemoresistant tumour cells can often result in tumour relapses and treatment failure. The mechanisms driving resistance to platinum compounds are numerous, and act via a diverse range of cellular processes, such as reducing uptake of the drug, increasing DNA repair activity, and reducing apoptotic signalling.

This study investigated whether the BET inhibitors, JQ-1 and I-BET726, were able to increase the sensitivity of parental and oxaliplatin-resistant Neuroblastoma (UKF-NB3) and cisplatin-resistant Ovarian cancer cell lines (COLO-704, EFO-21 and EFO-27) to their respective platinum compounds. BET inhibitor pre-treatments, using the IC10 and IC50 concentrations of JQ-1 and I-BET726 as single-agents for each cell line, resulted in increased sensitivity to the platinum compounds, as determined by MTT cell viability assays. Increasing the pre-treatment incubation duration from 0hrs to 24hrs and 48hrs improved the response to platinum agents, and the same effect was observed with increasing pre-treatment dosage. In summary, these results suggest that BET inhibitors are able to increase the sensitivity of cancer cells to platinum chemotherapeutics.

Item Type: Thesis (Master of Science by Research (MScRes))
Thesis advisor: Michaelis, Martin
Thesis advisor: Wass, Mark
Uncontrolled keywords: Cancer Chemoresistance Bromodomain Platinum Cisplatin Oxaliplatin Neuroblastoma OvarianCancer
SWORD Depositor: System Moodle
Depositing User: System Moodle
Date Deposited: 11 Oct 2017 13:12 UTC
Last Modified: 22 Jan 2020 04:10 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/63954 (The current URI for this page, for reference purposes)
  • Depositors only (login required):

Downloads

Downloads per month over past year